8-K: Certara Reports Mixed Q1 2024 Results: Software Growth Offsets Services Decline

Certara's first quarter of 2024 saw a 7% revenue increase driven by strong software growth, but a net loss due to increased operating expenses.

Summary

• Certara's total revenue for Q1 2024 reached $96.7 million, a 7% increase year-over-year, or 6% on a constant currency basis.
• Software revenue grew by 19% to $39.3 million, while services revenue remained flat at $57.3 million compared to Q1 2023.
• The company experienced a net loss of $4.7 million, a decrease from a net income of $1.4 million in the same period last year, primarily due to increased operating expenses.
• Adjusted EBITDA decreased to $29.1 million from $32.3 million in Q1 2023.
• Total bookings declined by 6% to $105.8 million, with software bookings up 8% and services bookings down 11%.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While software growth is positive, the net loss and decline in adjusted EBITDA are concerning. The reiteration of full-year guidance provides some stability, but the mixed results temper overall optimism.

Positives

• Software revenue experienced strong growth of 19% year-over-year.
• The software business demonstrated a high Net Retention Ratio of 114%.
• The company is reiterating its full-year 2024 financial guidance.
• Certara's strategic investments in software capabilities and commercial expansion are progressing as planned.

Negatives

• The company experienced a net loss of $4.7 million, a significant decrease from the net income of $1.4 million in Q1 2023.
• Adjusted EBITDA decreased by $3.2 million year-over-year.
• Total bookings declined by 6% year-over-year.
• Services bookings saw a decline of 11% year-over-year.
• Operating expenses increased by $10.7 million compared to the same quarter last year.

Risks

• The company faces risks related to competition within its market.
• There is a risk of deceleration in the acceptance of model-informed biopharmaceutical discovery.
• Changes or delays in government regulations could impact the business.
• Economic conditions, including inflation and currency fluctuations, pose a risk.
• The company is exposed to risks related to delays or cancellations in projects due to supply chain issues or clinical trial delays experienced by customers.
• The company faces risks related to its ability to retain key personnel and recruit qualified staff.
• There are risks associated with the use of artificial intelligence and machine learning in their products and services.
• The company's ability to meet obligations under indebtedness and have sufficient capital to operate the business is a risk.

Future Outlook

Certara is reiterating its full-year 2024 financial guidance, expecting revenue between $385 million and $400 million, adjusted EBITDA margin between 31-33%, and adjusted diluted earnings per share between $0.41 and $0.46.

Management Comments

• William F. Feehery, Chief Executive Officer, stated he is pleased with the first quarter financial results, driven by solid execution across both software and services.
• John Gallagher, Chief Financial Officer, noted the strong financial performance in software, driven by a 114% Net Retention Ratio, and that the services business performed in line with expectations.

Industry Context

The results reflect the growing importance of biosimulation in drug development, with Certara's software segment showing strong growth. However, the flat services revenue and overall net loss highlight the challenges in balancing growth with increased operating expenses in the current market.

Comparison to Industry Standards

• Certara's 19% software revenue growth is strong compared to some established SaaS companies in the healthcare space, such as Veeva Systems, which has seen growth in the mid-teens.
• The 114% Net Retention Rate is a positive indicator of customer satisfaction and stickiness, which is a key metric for SaaS businesses and compares favorably to industry benchmarks.
• The decline in services bookings is a concern, as many companies in the life sciences consulting space are seeing growth in this area, such as IQVIA and Syneos Health.
• The net loss and decrease in adjusted EBITDA are below the performance of some of its peers, such as Simulations Plus, which has maintained profitability.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decline in adjusted EBITDA.
• Employees may be impacted by the company's focus on cost management.
• Customers may benefit from the continued investment in software capabilities.
• Suppliers may see a potential impact from the company's financial performance.
• Creditors may be monitoring the company's debt levels and financial health.

Next Steps

• Certara will host a conference call on May 7, 2024, to discuss the first quarter 2024 financial results.
• The company intends to use its website as a means of disclosing material, non-public information.

Key Dates

Keywords

biosimulation, software, pharmaceutical, revenue, EBITDA, bookings, drug development, net loss, financial results, biotechnology